CN203915219U - Lacrimal ductule resistance core - Google Patents
Lacrimal ductule resistance core Download PDFInfo
- Publication number
- CN203915219U CN203915219U CN201420161476.9U CN201420161476U CN203915219U CN 203915219 U CN203915219 U CN 203915219U CN 201420161476 U CN201420161476 U CN 201420161476U CN 203915219 U CN203915219 U CN 203915219U
- Authority
- CN
- China
- Prior art keywords
- resistance core
- lacrimal
- resistance
- lacrimal ductule
- ductule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00772—Apparatus for restoration of tear ducts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12159—Solid plugs; being solid before insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/12036—Type of occlusion partial occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/0084—Material properties low friction
- A61B2017/00849—Material properties low friction with respect to tissue, e.g. hollow organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00893—Material properties pharmaceutically effective
Abstract
The utility model discloses a kind of lacrimal ductule resistance core, comprise resistance core print end and body.Resistance core print end is without the oblate column of corner angle or hemispherical, reduces the damage to eye table cell.Be used for stoping tear to flow in lacrimal passage, improve lacrimal river height, facilitate doctor to take out.Body is straight type or bending, above has several anticreep bolts, prevents from hindering core and deviates from, and body far-end attenuates, and is conducive to doctor's operation.By analysis of experiments, it can treat xerophthalmia, alleviates corneal laser surgery and the postoperative eyes discomfort causing of cataract operation, and the lacrimal passage after prevention soda acid burn narrows, and can also treat lacrimal duct injury fracture as indwelling tube.
Description
Technical field
This utility model relates to technical field of medical instruments, relates in particular to a kind of lacrimal ductule resistance core that is used for the treatment of ocular disease.
Background technology
Xerophthalmia refers to that tear reduce or lacrimal gland function declines and causes that eyes are dry and astringent, eye acid, ophthalmic pruritus, keep in dark place, the symptom such as visual deterioration, its harmed eye cornea, there will be keratomalacia to bore a hole when serious.
The method for the treatment of xerophthalmia is puncta Embolization at present.The method is by implanting lacrimal passage thromboembolism, seals tear and gets rid of pipeline.The method can be preserved the natural tear of lacrimal passage self secretion, and extends the time that tear stops on eye surface.According to the state of an illness, sometimes also need to be at a puncta embolus of the each implantation of upper and lower lacrimal passage.Due to lacrimal passage bolt curtailment, no matter be degradability or permanent lacrimal passage bolt, all can not treat preferably xerophthalmia.Puncta embolus is implanted to after lacrimal passage, need to puncta embolus be developed by performing an operation.If puncta embolus falls in lachrymal sac, will easily cause dacryocystisis.
In addition, for the lacrimal passage causing after the soda acid burn symptom that narrows, there is no at present ripe Prevention means.The malaise symptoms that after patient's corneal laser surgery or cataract operation, eyes are felt, does not have good treatment means yet.Lacrimal duct injury breaks with lacrimal passage often, conventionally can adopt indwelling tube to treat, but will leave obvious adnexa at patient's face after the method treatment, and there is obvious foreign body in patient face, and patient can be because of the bad generation mental maladjustment of image appearance.
Summary of the invention
Based on this, this utility model is to overcome the defect of prior art, and a kind of lacrimal ductule resistance core of being convenient to implant lacrimal passage and take out from lacrimal passage is provided.
Its technical scheme is as follows: a kind of lacrimal ductule resistance core, comprise resistance core body, described resistance core body one end has tip, the described resistance core body other end has resistance core print end, described resistance core print end is without the oblate column of corner angle or hemispherical, described resistance core body is provided with several anticreep bolts, and described anticreep bolt is to be arranged on the cone boss that on described resistance core body, diameter increases gradually towards described resistance core print end.
Preferably, described resistance core body is connected and composed by the first end of the first body and the first end of the second body, between described the first body and described the second body, angle is 30 ° to 150 °, and the second end of described the first body has resistance core print end, and the second end of described the second body has tip.
Preferably, described the first body and described the second body junction arc transition, and between described the first body and the second body, angle is 90 °.In the time that resistance core body is L-shaped, the shape in this shape and natural lacrimal passage chamber is coincide, and after the lacrimal ductule resistance core of L shaped shape is implanted in lacrimal passage, lacrimal ductule resistance core is more firm in lacrimal passage, under not understanding, slides into lacrimal passage, is also difficult for rubbing one's eyes and drops out, and position is fixed for a long time.
Preferably, described in one of them, anticreep bolt has replaced described tip.
Preferably, on described resistance core outer surface of tube body, be furnished with a lot of dots or spiral lines.Arranging dot at resistance core outer surface of tube body, or spiral lines, increase the friction effect that hinders core outer surface of tube body and lacrimal passage, avoid lacrimal ductule resistance core to skid off easily lacrimal passage, strengthen the firm effect of lacrimal ductule resistance core at lacrimal passage.
Preferably, described resistance core body and described resistance core print end are by absorbable material processing and manufacturing.This kind of absorbable material and regenerative cell are sticky glutinous, can keep lacrimal passage shape, therefore, after soda acid burn, the histiocyte of hypertrophy can not stick to resistance core body surface, and the prevention lacrimal passage effect that narrows is remarkable, secondly, the lacrimal ductule resistance core of this kind of material can adsorb medicine and trophic factors, medicine and trophic factors can be coated in lacrimal ductule resistance wicking surface and carry out administration, and therefore, the effect that is used for treating xerophthalmia is particularly remarkable.
Preferably, in described resistance core body, be provided with cavity, described resistance core body offers the some micropores that lead to described cavity.Holding medicine or trophic factors etc. in cavity, can make it slowly after release, be absorbed by eyes by this micropore, and can be according to the aperture of micropore and quantity control drug releasing rate, can treat preferably eyes soda acid burn symptom and xerophthalmia.
Preferably, described tip is round blunt shape, and described resistance core body is provided with axially extending bore.This kind of lacrimal ductule resistance core implanted to lacrimal passage, because tip is round blunt shape, most advanced and sophisticated implantation in lacrimal passage process, the pain of patient's eye alleviates, lacrimal ductule resistance in-core arranges axially extending bore can allow the unnecessary tear of lacrimal passage be flowed out outside eyes by the through hole that hinders core body, keeps in lacrimal passage tear moderate with this.
Preferably, described resistance core body length is 2～20mm, and resistance core pipe diameter is 0.4～1.5mm; Resistance core print end thickness is 0.1～0.5mm, and resistance core print end diameter is 0.6～1.8mm.Resistance core body is suitable for the treatment of different patient's lacrimal passages, and resistance core body long enough, probes into after lacrimal passage, shape can be out of shape with the bending of lacrimal passage, contacts firmly, and then slide into lacrimal passage under not understanding so lacrimal ductule hinders core with lacrimal passage, also be difficult for rubbing one's eyes and drop out, position is fixing for a long time.
Preferably, described resistance core body length is 6～14mm, and resistance core pipe diameter is 0.5～1.0mm; Resistance core print end thickness is 0.2～0.3mm, and resistance core print end diameter is 0.7～1.3mm.
Below principle, the effect etc. of aforementioned techniques scheme are described:
First, lacrimal ductule resistance core has tip, easily lacrimal ductule is hindered to core and implants lacrimal passage; Lacrimal ductule resistance core has head end, can be convenient to be clipped head end by tweezers lacrimal ductule is hindered to core implantation lacrimal passage, implantation finishes rear puncta mouth and leaves head end, head end is convenient to be clipped from lacrimal passage and take out by tweezers, therefore not needing, by performing an operation, lacrimal ductule is hindered to core develops, in addition, head end can make lacrimal river height improve simultaneously.Secondly,, in the time that head end is the oblate column without corner angle, because head end does not have corner angle, harmed eye histiocyte degree is low; When head end is while being hemispherical, hemispherical head end does not have corner angle, can not make patient have foreign body sensation, and harmed eye histiocyte degree is low.Through analysis of experiments, it can treat xerophthalmia, can also prevent after soda acid burn the lacrimal passage symptom that narrows, and can also treat lacrimal duct injury fracture symptom as indwelling tube, and be used for the treatment of the eyes malaise symptoms after corneal laser surgery, and therapeutic effect is remarkable.
Brief description of the drawings
Fig. 1 is the structural representation of lacrimal ductule resistance core described in the utility model;
Fig. 2 is the side view of Fig. 1;
Fig. 3 is the structural representation of lacrimal ductule resistance core described in this utility model embodiment mono-;
Fig. 4 is the structural representation of lacrimal ductule resistance core described in this utility model embodiment bis-;
Fig. 5 is the structural representation of lacrimal ductule resistance core described in this utility model embodiment tri-;
Fig. 6 is the structural representation one that lacrimal ductule resistance core has cone boss described in this utility model embodiment;
Fig. 7 is the structural representation two that lacrimal ductule resistance core has cone boss described in this utility model embodiment;
Fig. 8 is the structural representation three that lacrimal ductule resistance core has cone boss described in this utility model embodiment;
Fig. 9 is the structural representation four that lacrimal ductule resistance core has cone boss described in this utility model embodiment;
Figure 10 is the structural representation five that lacrimal ductule resistance core has cone boss described in this utility model embodiment.
Description of reference numerals:
1, resistance core body, 11, the first body, 12, the second body, 2, resistance core print end, 3, tip, 4, micropore, 5, cavity, 6, through hole, 7, cone boss.
Detailed description of the invention
Below embodiment of the present utility model is elaborated:
As depicted in figs. 1 and 2, lacrimal ductule resistance core described in the utility model, comprises resistance core body 1, and described resistance core body 1 one end has tip 3, and described resistance core body 1 other end has resistance core print end 2, and described resistance core print end 2 is without the oblate column of corner angle or hemispherical.
First, lacrimal ductule resistance core has tip 3, easily lacrimal ductule is hindered to core and implants lacrimal passage; Lacrimal ductule resistance core has head end, can be convenient to be clipped head end by tweezers lacrimal ductule is hindered to core implantation lacrimal passage, implantation finishes rear puncta mouth and leaves head end, head end is convenient to be clipped from lacrimal passage and take out by tweezers, therefore not needing, by performing an operation, lacrimal ductule is hindered to core develops, in addition, head end can make lacrimal river height improve simultaneously.Secondly,, in the time that head end is the oblate column without corner angle, because head end does not have corner angle, harmed eye histiocyte degree is low; When head end is while being hemispherical, hemispherical head end does not have corner angle, can not make patient have foreign body sensation, and harmed eye histiocyte degree is low.By analysis of experiments, it can treat xerophthalmia, can also prevent after soda acid burn the lacrimal passage symptom that narrows, and can also treat lacrimal duct injury fracture symptom as indwelling tube, and be used for the treatment of the eyes malaise symptoms after corneal laser surgery, and therapeutic effect is remarkable.
In addition, due to resistance core body 1 long enough, only need in patient's lacrimal passage, implant a lacrimal ductule resistance core, implant after lacrimal passage, lacrimal ductule resistance core shape can be out of shape with the bending of lacrimal passage, and lacrimal ductule resistance core contacts firmly with lacrimal passage, and then slides into lacrimal passage under not understanding, also be difficult for rubbing one's eyes and drop out, position is fixing for a long time.Due to resistance core body 1 long enough, implant from lower lacrimal passage, can arrive upper and lower lacrimal passage intersection, only need a lacrimal ductule hinder core and just can seal upper and lower two lacrimal passages simultaneously.
According to the lacrimal passage length of different people, provide and be applicable to the different patient's lacrimal ductule resistance for the treatment of core size below:
Described resistance core body 1 is long is 2mm, and resistance core body 1 diameter is 0.4mm; Resistance core print end 2 thickness are 0.1mm, and resistance core print end 2 diameters are 0.6mm.The lacrimal ductule resistance core of this kind of size is implanted to after the lacrimal passage of xerophthalmia patient A to rehabilitation in 28 days.
Described resistance core body 1 is long is 10mm, and resistance core body 1 diameter is 1mm; Resistance core print end 2 thickness are 0.3mm, and resistance core print end 2 diameters are 1.2mm.The lacrimal ductule resistance core of this kind of size is implanted to after the lacrimal passage of xerophthalmia patient B, and rehabilitation in 36 days, is implanted to the lacrimal ductule resistance core of this kind of size after the lacrimal passage of the patient C being burnt by soda acid, and preventive effect is good, and lacrimal passage does not narrow, rehabilitation in 96 days.
Described resistance core body 1 is long is 20mm, and resistance core body 1 diameter is 1.5mm; Resistance core print end 2 thickness are 0.5mm, and resistance core print end 2 diameters are 1.8mm.Xerophthalmia patient D uses after the lacrimal ductule resistance core of this kind of size every day, rehabilitation in 37 days, and the patient E being burnt by soda acid uses after the lacrimal ductule resistance core of this kind of size every day, and preventive effect is good, and lacrimal passage does not narrow, rehabilitation in 100 days.
Described resistance core body 1 is long is 6mm, and resistance core body 1 diameter is 0.5mm; Resistance core print end 2 thickness are 0.2mm, and resistance core print end 2 diameters are 0.7mm.The lacrimal ductule resistance core of this kind of size is implanted to after the lacrimal passage of laser surgery patient F to rehabilitation in 30 days.
Described resistance core body 1 is long is 8mm, and resistance core body 1 diameter is 0.7mm; Resistance core print end 2 thickness are 0.2mm, and resistance core print end 2 diameters are 1.0mm.The lacrimal ductule resistance core of this kind of size is implanted to after the lacrimal passage of laser surgery patient G, and rehabilitation in 32 days, is implanted to the lacrimal ductule resistance core of this kind of size after the lacrimal passage of patient H of laceration of lacrimal canaliculus rehabilitation in 99 days.
Described resistance core body 1 is long is 14mm, and resistance core body 1 diameter is 1.0mm; Resistance core print end 2 thickness are 0.3mm, and resistance core print end 2 diameters are 1.3mm.The lacrimal ductule resistance core of this kind of size is implanted to after laser surgery patient I, and rehabilitation in 37 days, is implanted to the lacrimal ductule resistance core of this kind of size after the lacrimal passage of patient J of laceration of lacrimal canaliculus rehabilitation in 92 days.
The above-mentioned example providing, is the inside clinical trial of our company, from patient A to patient J, has replaced patient name, the internal data that Shi Ben hospital retains when for patient treatment with letter.Other patient's conditions are similar, and this utility model does not provide one by one at this.
Sum up and learn from above-mentioned clinical trial:
When resistance core body 1 length is during at 2～20mm, this length is remarkable as treatment xerophthalmia effect, and its lacrimal ductule resistance core long enough, implants from lower lacrimal passage, can arrive upper and lower lacrimal passage intersection, only need a lacrimal ductule hinders core and just can seal upper and lower two lacrimal passages simultaneously.
In the time hindering core body 1 length at 8～20mm, be relatively suitable for preventing the lacrimal passage after soda acid burn to narrow, its resistance core body 1 length is to determine according to the degree of acid-base pair lacrimal passage burn, its scope is often chosen at 2～20mm.
Secondly, lacrimal ductule resistance core described in the utility model can also be used for the treatment of the eyes discomfort after corneal laser surgery or cataract operation, also be lacrimal ductule to be hindered to core be implanted in lacrimal passage, its length is identical with the length range of xerophthalmia lacrimal ductule resistance core used, specifically selects length to determine according to patient's eye lacrimal passage length.
Again, lacrimal ductule resistance core of the present utility model can also be worked as indwelling tube and be treated lacrimal duct injury fracture symptom, the length that its resistance core body 1 is selected is often at 7mm～20mm, because the lacrimal ductule resistance core that resistance core body 1 length is 7 mm～20mm can seal whole piece lacrimal passage, different breakaway poings can be covered by resistance core body 1, and therapeutic effect is good.Lacrimal duct injury breaks with lacrimal passage often, and prior art adopts indwelling tube to treat conventionally, but will leave obvious adnexa at patient's face after the method treatment, and there is obvious foreign body sensation in patient face, and outward appearance is also bad, causes mental maladjustment to patient.And adopt after lacrimal ductule resistance core described in the utility model, it is convenient to implant, and after wound healing, takes out lacrimal ductule resistance core also rather convenient simultaneously, and still can keep the shape of lacrimal passage.
Wherein, resistance core body 1 described in the utility model is selected absorbable material processing and manufacturing with described resistance core print end 2, for example, can select chitosan to carry out processing and manufacturing.Can certainly select nonabsorable material to manufacture, as selected medical silica-gel materials processing manufacture or polyene, the processing and manufacturing of polyesters medical macromolecular materials, this kind of material and regenerative cell are sticky glutinous, can keep lacrimal passage shape, therefore, after soda acid burn, the histiocyte of hypertrophy does not stick on lacrimal ductule resistance core, the prevention lacrimal passage effect that narrows is remarkable, secondly, the lacrimal ductule resistance core of this kind of material can adsorb medicine and trophic factors, medicine and trophic factors can be coated in lacrimal ductule resistance wicking surface and carry out administration, and therefore, the effect that is used for treating xerophthalmia is also particularly remarkable.Because there are production in chitosan, medical silica-gel material or polyene, polyesters medical macromolecular materials lot of domestic and international producer, not new material, as long as meet medical specification, therefore, this utility model does not repeat them here.
Embodiment mono-, as shown in Figure 3, described most advanced and sophisticated 3 are round blunt shape, and described resistance core body 1 is provided with axially extending bore 6.This kind of lacrimal ductule resistance core implanted, and the axially extending bore 6 that lacrimal ductule resistance core has is that treatment xerophthalmia effect is remarkable for unnecessary tear can be flowed out outside lacrimal passage through the axially extending bore 6 of lacrimal ductule resistance core, keeping the tear of lacrimal passage moderate.In an embodiment, on described resistance core body 1 outer surface, be furnished with a lot of dots or spiral lines therein.Arranging dot at resistance core body 1 outer surface, or spiral lines, the friction effect between resistance core body 1 surface and lacrimal passage can be increased.
Embodiment bis-, as shown in Figure 4, is provided with cavity 5 in described resistance core body 1, cavity 5 drug-carryings, and described resistance core body 1 offers the some micropores 4 that lead to described cavity 5, micropore 4 releasable medicaments.By from resistance core print end 2 to the interior injectable drug of cavity 5 or trophic factors etc., medicine or trophic factors etc. are slowly infiltrated in lacrimal passage and are absorbed by eyes by this micropore 4, can treat preferably eyes discomfort and lacrimal duct injury fracture symptom after eyes soda acid burn symptom, xerophthalmia, corneal laser surgery.
Embodiment tri-, as shown in Figure 5, one end of described resistance core body 1 one end by the first body 11 and the second body 12 connects and composes, between described the first body 11 and described the second body 12, angle is 30 degree to 150 degree, the other end of described the first body 11 has resistance core print end 2, and the other end of described the second body 12 has most advanced and sophisticated 3.Described the first body 11 and described the second body 12 junction arc transition, and described the first body 11 is overall L-shaped with the second body 12.In the time that resistance core body 1 is L-shaped, the shape in this shape and natural lacrimal passage chamber is more identical, after the lacrimal ductule resistance core of this kind of L shaped shape is implanted in lacrimal passage, lacrimal ductule resistance core is more firm in lacrimal passage, under not understanding, slide into lacrimal passage, be also difficult for rubbing one's eyes and drop out, position is fixing for a long time.Due to patient history complexity, may be tortuous or of flaccid muscles in lacrimal passage, lacrimal ductule resistance core easily skids off lacrimal passage, therefore, refer to Fig. 6-10, Fig. 6-10th, this utility model hinders several structural representations on core body with anticreep bolt, described resistance core body 1 is provided with several anticreep bolts, described anticreep bolt is to be arranged on the cone boss that on described the first body 11, diameter increases gradually towards described resistance core print end, and/or is arranged on the cone boss that on described the second body 12, diameter reduces gradually towards described tip.Wherein as shown in figure 10, the tip of resistance core body 1 is replaced by anticreep bolt.The frictional force that anticreep bolt can increase resistance core body 1 and eye lacrimal passage is set, improves resistance core body 1 steadiness at eye lacrimal passage, avoid lacrimal ductule resistance core to skid off lacrimal passage phenomenon.
The above embodiment has only expressed detailed description of the invention of the present utility model, and it describes comparatively concrete and detailed, but can not therefore be interpreted as the restriction to this utility model the scope of the claims.It should be pointed out that for the person of ordinary skill of the art, without departing from the concept of the premise utility, can also make some distortion and improvement, these all belong to protection domain of the present utility model.
Claims (10)
1. a lacrimal ductule resistance core, it is characterized in that, comprise resistance core body, described resistance core body one end has tip, the described resistance core body other end has resistance core print end, described resistance core print end is without the oblate column of corner angle or hemispherical, and described resistance core body is provided with several anticreep bolts, and described anticreep bolt is to be arranged on the cone boss that on described resistance core body, diameter increases gradually towards described resistance core print end.
2. lacrimal ductule resistance core according to claim 1, it is characterized in that, described resistance core body is connected and composed by the first end of the first body and the first end of the second body, between described the first body and described the second body, angle is 30 ° to 150 °, the second end of described the first body has resistance core print end, and the second end of described the second body has tip.
3. lacrimal ductule resistance core according to claim 2, is characterized in that, described the first body and described the second body junction arc transition, and between described the first body and the second body, angle is 90 °.
4. lacrimal ductule resistance core according to claim 3, is characterized in that, described in one of them, anticreep bolt has replaced described tip.
5. lacrimal ductule resistance core according to claim 3, is characterized in that, described resistance core outer surface of tube body is furnished with a lot of dots or spiral lines.
6. lacrimal ductule resistance core according to claim 1, is characterized in that, described resistance core body and described resistance core print end are absorbable material processing and manufacturing.
7. lacrimal ductule resistance core according to claim 1, is characterized in that, in described resistance core body, be provided with cavity, described resistance core body offers the some micropores that lead to described cavity.
8. lacrimal ductule resistance core according to claim 1, is characterized in that, described tip is round blunt shape, and described resistance core body is provided with axially extending bore.
9. lacrimal ductule resistance core according to claim 1, is characterized in that, described resistance core body length is 2～20mm, and resistance core pipe diameter is 0.4～1.5mm; Resistance core print end thickness is 0.1～0.5mm, and resistance core print end diameter is 0.60～1.8mm.
10. lacrimal ductule resistance core according to claim 9, is characterized in that, described resistance core body length is 6～14mm, and resistance core pipe diameter is 0.5～1.0mm; Resistance core print end thickness is 0.2～0.3mm, and resistance core print end diameter is 0.70～1.3mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420161476.9U CN203915219U (en) | 2013-07-15 | 2014-04-03 | Lacrimal ductule resistance core |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103042139A CN103349588A (en) | 2013-07-15 | 2013-07-15 | Lacrimal ductile blocking core |
| CN201310304213.9 | 2013-07-15 | ||
| CN201420161476.9U CN203915219U (en) | 2013-07-15 | 2014-04-03 | Lacrimal ductule resistance core |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203915219U true CN203915219U (en) | 2014-11-05 |
Family
ID=49306075
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103042139A Pending CN103349588A (en) | 2013-07-15 | 2013-07-15 | Lacrimal ductile blocking core |
| CN201420161476.9U Expired - Fee Related CN203915219U (en) | 2013-07-15 | 2014-04-03 | Lacrimal ductule resistance core |
| CN201410133949.9A Pending CN103876887A (en) | 2013-07-15 | 2014-04-03 | Lacrimal ductule stopping core |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103042139A Pending CN103349588A (en) | 2013-07-15 | 2013-07-15 | Lacrimal ductile blocking core |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410133949.9A Pending CN103876887A (en) | 2013-07-15 | 2014-04-03 | Lacrimal ductule stopping core |
Country Status (2)
| Country | Link |
|---|---|
| CN (3) | CN103349588A (en) |
| WO (2) | WO2015006999A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106344257A (en) * | 2016-08-31 | 2017-01-25 | 李志强 | Lacrimal plug adjustable in scale of plug bodies |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103349588A (en) * | 2013-07-15 | 2013-10-16 | 广州卫视博生物科技有限公司 | Lacrimal ductile blocking core |
| CN104984410A (en) * | 2015-07-29 | 2015-10-21 | 陕西博与再生医学有限公司 | Controllable-degradation lacrimal passage suppository and preparation method thereof |
| CN106667656A (en) * | 2016-06-30 | 2017-05-17 | 广州聚明生物科技有限公司 | Biodegradable lacrimal passage suppository and preparation method and application thereof |
| CN106491270B (en) * | 2016-12-23 | 2018-08-14 | 中国医科大学附属第一医院 | A kind of lacrimal point extension fixture |
| CN110711075A (en) * | 2018-07-11 | 2020-01-21 | 吴坚 | Lacrimal duct embolism |
| EP4210598A1 (en) * | 2020-09-10 | 2023-07-19 | Oasis Medical, Inc. | Devices and methods for occluding the punctal opening |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| FR2834446B1 (en) * | 2002-01-08 | 2004-02-13 | Ioltechnologie Production | EXPANDING MEATIC NAIL |
| CN100502956C (en) * | 2006-01-05 | 2009-06-24 | 天津市贝亿生物制品有限公司 | Collagen short stick using for dacryosolen embolism |
| US9173773B2 (en) * | 2006-06-21 | 2015-11-03 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
| CN104856782B (en) * | 2007-09-07 | 2017-09-12 | 马缇医疗股份有限公司 | Lacrimal implants and correlation technique |
| CN201108670Y (en) * | 2007-11-19 | 2008-09-03 | 丁明红 | Dredging conduit pipe for curing chronic dacryocystitis |
| CN102014816B (en) * | 2008-02-18 | 2015-04-15 | 马缇医疗股份有限公司 | Lacrimal implants and related methods |
| US8821457B2 (en) * | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| CN202505577U (en) * | 2012-04-09 | 2012-10-31 | 王秀丽 | Absorbable micro-penetration punctum plug and installation tool thereof |
| CN102688080B (en) * | 2012-06-05 | 2015-03-18 | 杭州柳茶医药科技有限公司 | Nasolacrimal duct embolism body capable of automatically adjusting tear amount and matched installation tool thereof |
| CN202875597U (en) * | 2012-09-10 | 2013-04-17 | 高传友 | Lacrimal passage stick placed in lacrimal passage for treatment of eye disease |
| CN103349588A (en) * | 2013-07-15 | 2013-10-16 | 广州卫视博生物科技有限公司 | Lacrimal ductile blocking core |
-
2013
- 2013-07-15 CN CN2013103042139A patent/CN103349588A/en active Pending
- 2013-07-31 WO PCT/CN2013/080552 patent/WO2015006999A1/en active Application Filing
-
2014
- 2014-04-03 CN CN201420161476.9U patent/CN203915219U/en not_active Expired - Fee Related
- 2014-04-03 CN CN201410133949.9A patent/CN103876887A/en active Pending
- 2014-06-25 WO PCT/CN2014/080700 patent/WO2015007139A1/en active Application Filing
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106344257A (en) * | 2016-08-31 | 2017-01-25 | 李志强 | Lacrimal plug adjustable in scale of plug bodies |
| CN106344257B (en) * | 2016-08-31 | 2018-07-10 | 李志强 | A kind of lacrimal passage bolt of body scalable |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015007139A1 (en) | 2015-01-22 |
| CN103876887A (en) | 2014-06-25 |
| CN103349588A (en) | 2013-10-16 |
| WO2015006999A1 (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN203915219U (en) | Lacrimal ductule resistance core | |
| JP2007536220A5 (en) | ||
| JP2013516215A (en) | Ophthalmic surgical apparatus and method for performing ophthalmic surgery | |
| CN104428023A (en) | Rounded-end device for preventing posterior capsular opacification | |
| CN205107976U (en) | Intraocular lens suitable for ligamentopexis between wicresoft sclera layer | |
| CN108324424A (en) | Lacrimal passage trepan is unimpeded to set guard system | |
| CN106344257B (en) | A kind of lacrimal passage bolt of body scalable | |
| CN109303637A (en) | A kind of eye drops assistor | |
| CN205235152U (en) | Eye drops is with supplementary glasses | |
| CN107874871A (en) | Implanted view membrane support | |
| CN206102827U (en) | Hierarchical slowly -releasing lacrimal point stopper | |
| CN206603846U (en) | Implanted view membrane support | |
| WO2019237749A1 (en) | Lamina cribrosa crossing pressure balance maintainer for constantly balancing lamina cribrosa crossing pressure difference, implantation device, and method for balancing lamina cribrosa crossing pressure difference | |
| Hirji et al. | Snailtrack corneal changes following subconjunctival injection of 5-fluorouracil | |
| Kumar et al. | Comparative analysis of outcome of management of pediatric cataract with and without primary posterior capsulotomy and anterior vitrectomy | |
| Huq et al. | Cataract surgery and phacoemulsification for the beginning surgeons | |
| CN207186742U (en) | Lacrimal passage trepan is unimpeded to put guard system | |
| CN206350867U (en) | A kind of internally-arranged type lacrimal passage drainage tubes | |
| Hussain et al. | Comparison of pain in patients with topical anaesthesia alone versus topical anaesthesia with intracameral lidocaine for phacoemulsification | |
| CN203773834U (en) | Teaching aid for hyphema | |
| O'Neill et al. | Author Spotlight: Unraveling Molecular Mechanisms in PCO and Fibrosis Following Cataract Surgery | |
| Ramsay | Clinical Ophthalmology for the General Practitioner | |
| Eradurman et al. | Results of cataract surgery in monocular patients | |
| CN202740213U (en) | Lacrimal passage embolus | |
| Kabat et al. | Make your brown eyes blue: a review of cosmetic procedures suggests that vanity often has a high cost |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141105 Termination date: 20200403 |